Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia
Phase II Efficacy Study of Intramuscular Autologous Bone Marrow Mononuclear Cells Plus Mesenchymal Stem Cell Implantation Versus Autologous Bone Marrow Mononuclear Cells Implantation Only in Patients With Chronic Critical Limb Ischemia
Sponsor: Cytopeutics Sdn. Bhd.
A PHASE2 clinical study on Critical Limb Ischemia, this trial is ongoing. The trial is conducted by Cytopeutics Sdn. Bhd. and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Unknown Status PHASE2
▶ Show 2 earlier versions
-
May 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2017 — May 2017 [monthly]
Recruiting PHASE2
First recorded
Mar 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cytopeutics Sdn. Bhd.
- National University of Malaysia
For direct contact, visit the study record on ClinicalTrials.gov .